Sarven Sabunciyan

Sarven Sabunciyan

Auto-generated profile, based on publicly available information

Sarven Sabunciyan

Department of Pediatrics, Stanley Division, Johns Hopkins University School of Medicine, United States

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2009 in Nature Genetics
Verified
Journal Article
Open access
PDF file
RIRafael A Irizarry
Rafael A Irizarry
CLChristine Ladd-Acosta
Christine Ladd-Acosta
BWBo Wen
Bo Wen
ZWZhijin Wu
Zhijin Wu
CMCarolina Montano
Carolina Montano
AFAndrew P Feinberg
Andrew P Feinberg
Andy Feinberg and colleagues show in a colon cancer model that most DNA methylation alterations occur in sequence regions distinct from promoters or canonical CpG islands, termed 'CpG island shores', and that this methylation is strongly related to gene expression and can discriminate tissue types regardless of species of origin. For the past 25 years, it has been known that alterations in DNA methylation (DNAm) occur in cancer, including hypomethylation of oncogenes and hypermethylation of tumor suppressor genes. However, most studies of cancer methylation have assumed that functionally important DNAm will occur in promoters, and that most DNAm changes in cancer occur in CpG islands. Here we show that most methylation alterations in colon cancer occur not in promoters, and also not in CpG islands, but in sequences up to 2 kb distant, which we term 'CpG island shores'. CpG island shore methylation was strongly related to gene expression, and it was highly conserved in mouse, discriminating tissue types regardless of species of origin. There was a notable overlap (45–65%) of the locations of colon cancer–related methylation changes with those that distinguished normal tissues, with hypermethylation enriched closer to the associated CpG islands, and hypomethylation enriched further from the associated CpG island and resembling that of noncolon normal tissues. Thus, methylation changes in cancer are at sites that vary normally in tissue differentiation, consistent with the epigenetic progenitor model of cancer, which proposes that epigenetic alterations affecting tissue-specific differentiation are the predominant mechanism by which epigenetic changes cause cancer.

26 June 2011 in Nature Genetics
Verified
Journal Article
Open access
PDF file
KHKasper Daniel Hansen
Kasper Daniel Hansen
WTWinston Timp
Winston Timp
HBHéctor Corrada Bravo
Héctor Corrada Bravo
SSSarven Sabunciyan
Sarven Sabunciyan
BLBenjamin Langmead
Benjamin Langmead
AFAndrew P Feinberg
Andrew P Feinberg
Andrew Feinberg and colleagues report whole-genome bisulfite sequencing of three colon cancers and matched normal tissue and two adenomatous polyps. The authors identify large blocks of relative hypomethylation over half of the genome. Tumor heterogeneity is a major barrier to effective cancer diagnosis and treatment. We recently identified cancer-specific differentially DNA-methylated regions (cDMRs) in colon cancer, which also distinguish normal tissue types from each other, suggesting that these cDMRs might be generalized across cancer types. Here we show stochastic methylation variation of the same cDMRs, distinguishing cancer from normal tissue, in colon, lung, breast, thyroid and Wilms' tumors, with intermediate variation in adenomas. Whole-genome bisulfite sequencing shows these variable cDMRs are related to loss of sharply delimited methylation boundaries at CpG islands. Furthermore, we find hypomethylation of discrete blocks encompassing half the genome, with extreme gene expression variability. Genes associated with the cDMRs and large blocks are involved in mitosis and matrix remodeling, respectively. We suggest a model for cancer involving loss of epigenetic stability of well-defined genomic domains that underlies increased methylation variability in cancer that may contribute to tumor heterogeneity.

1 February 2018 in Schizophrenia Research
Verified
Journal Article
Closed access
ESEmanuel Schwarz
Emanuel Schwarz
JMJohanna Maukonen
Johanna Maukonen
THTiina Hyytiäinen
Tiina Hyytiäinen
TKTuula Kieseppä
Tuula Kieseppä
Matej OresicMatej Oresic
Matej Oresic
Jaana SuvisaariJaana Suvisaari
Jaana Suvisaari

1 December 2007 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
CLChristine Ladd-Acosta
Christine Ladd-Acosta
JPJonathan Pevsner
Jonathan Pevsner
SSSarven Sabunciyan
Sarven Sabunciyan
RYRobert H. Yolken
Robert H. Yolken
MWMaree J. Webster
Maree J. Webster
AFAndrew P. Feinberg
Andrew P. Feinberg

1 May 2016 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
CMCarolina Montano
Carolina Montano
MTMargaret A. Taub
Margaret A. Taub
AJAndrew Jaffe
Andrew Jaffe
EBEirikur Briem
Eirikur Briem
JFJason I. Feinberg
Jason I. Feinberg
AFAndrew P. Feinberg
Andrew P. Feinberg
Schizophrenia (SZ) is a neurodevelopmental disorder affecting 1% of the population worldwide, often resulting in lifelong disability.1 Treatments are not efficacious for the most disabling symptoms such as deficits in working memory, attention, and social cognition.2 Understanding the underlying biology of SZ can inform both treatment and prevention strategies. Heritability estimates are high (70%-81%) and some genetic variants have now been identified3 including multiple common variants,4,5 copy number variants,6 and rare mutations.7,8 The Psychiatric Genomics Consortium has identified 108 loci9; despite its size, this study has highlighted modest effect sizes and the importance of regulatory DNA.10 Mechanistic studies in transgenic animals have significant limitations because animal models have different brain structures and cannot fully recapitulate the phenotypic components of SZ.11

25 September 2013 in Genome Research
Verified
Journal Article
Open access
PDF file
KHKasper D. Hansen
Kasper D. Hansen
SSSarven Sabunciyan
Sarven Sabunciyan
BLBen Langmead
Ben Langmead
NNNoemi Nagy
Noemi Nagy
RCRebecca Curley
Rebecca Curley
AFAndrew P. Feinberg
Andrew P. Feinberg
Altered DNA methylation occurs ubiquitously in human cancer from the earliest measurable stages. A cogent approach to understanding the mechanism and timing of altered DNA methylation is to analyze it in the context of carcinogenesis by a defined agent. Epstein-Barr virus (EBV) is a human oncogenic herpesvirus associated with lymphoma and nasopharyngeal carcinoma, but also used commonly in the laboratory to immortalize human B-cells in culture. Here we have performed whole-genome bisulfite sequencing of normal B-cells, activated B-cells, and EBV-immortalized B-cells from the same three individuals, in order to identify the impact of transformation on the methylome. Surprisingly, large-scale hypomethylated blocks comprising two-thirds of the genome were induced by EBV immortalization but not by B-cell activation per se. These regions largely corresponded to hypomethylated blocks that we have observed in human cancer, and they were associated with gene-expression hypervariability, similar to human cancer, and consistent with a model of epigenomic change promoting tumor cell heterogeneity. We also describe small-scale changes in DNA methylation near CpG islands. These results suggest that methylation disruption is an early and critical step in malignant transformation.